Citius Oncology Finalizes $6.1M Warrant Exercise at Premium, Reports Positive Phase 1 LYMPHIR Data at ASCO
CTOR sits 61% above its 52-week low of $0.491 on light trading volume (0.4× avg).
Summary
Citius Oncology finalized a $6.1 million capital raise from warrant exercises at a premium price, while also announcing positive Phase 1 clinical data for LYMPHIR at the ASCO Annual Meeting, providing a dual boost to its financial stability and product pipeline.
Key Events · Financing and Capital Events · CTOR
-
Warrant Exercise Finalized
The company finalized the exercise of 6,818,182 warrants at a reduced price of $0.90 per share, generating approximately $6.1 million in net proceeds. This exercise price was at a premium to the last reported closing price of $0.798 on May 29, 2026, indicating investor confidence.
-
Positive Phase 1 Clinical Data Presented at ASCO
Citius Oncology highlighted positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the ASCO Annual Meeting. Key findings include a 24% Overall Response Rate (ORR), 48% of patients achieving clinical benefit, and a median progression-free survival (mPFS) of 20.5 months among those with clinical benefit, with manageable tolerability.
-
Addresses Going Concern
The $6.1 million capital raise is a significant inflow for the company, which recently reported substantial doubt about its ability to continue as a going concern, providing crucial funding to extend its operational runway.
Analysis · CTOR · Life Sciences
This filing is highly important as it addresses two critical areas for Citius Oncology: capital and clinical development. The company finalized a $6.1 million capital raise through warrant exercises, which is substantial for a company facing 'going concern' issues. The fact that these warrants were exercised at a premium to the recent market price indicates investor confidence. Concurrently, the announcement of positive Phase 1 clinical data for LYMPHIR in a new indication at ASCO provides a significant boost to the company's product pipeline and future revenue potential, offering a strong positive signal for its oncology assets.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.7M. The 52-week trading range was $0.49 to $6.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.